Agios spot­lights promis­ing da­ta for IDH1 drug, putting it on the path to FDA sub­mis­sion

Agios to­day played a few of the cards it plans to show the FDA lat­er this year when it files for an ap­proval of its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland